GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CareDx Inc (NAS:CDNA) » Definitions » Cyclically Adjusted Price-to-FCF

CDNA (CareDx) Cyclically Adjusted Price-to-FCF : (As of Jun. 28, 2025)


View and export this data going back to 2014. Start your Free Trial

What is CareDx Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


CareDx Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for CareDx's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CareDx Cyclically Adjusted Price-to-FCF Chart

CareDx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CareDx Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CareDx's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, CareDx's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CareDx's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CareDx's Cyclically Adjusted Price-to-FCF falls into.


;
;

CareDx Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

CareDx's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, CareDx's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.511/134.9266*134.9266
=-0.511

Current CPI (Mar. 2025) = 134.9266.

CareDx Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.178 100.684 -0.239
201509 -0.288 100.392 -0.387
201512 -0.340 99.792 -0.460
201603 -0.526 100.470 -0.706
201606 -0.459 101.688 -0.609
201609 -0.080 101.861 -0.106
201612 -0.140 101.863 -0.185
201703 -0.319 102.862 -0.418
201706 -0.150 103.349 -0.196
201709 -0.099 104.136 -0.128
201712 -0.080 104.011 -0.104
201803 -0.155 105.290 -0.199
201806 -0.211 106.317 -0.268
201809 -0.006 106.507 -0.008
201812 0.026 105.998 0.033
201903 -0.154 107.251 -0.194
201906 0.058 108.070 0.072
201909 0.004 108.329 0.005
201912 -0.054 108.420 -0.067
202003 -0.111 108.902 -0.138
202006 0.450 108.767 0.558
202009 0.020 109.815 0.025
202012 0.137 109.897 0.168
202103 -0.705 111.754 -0.851
202106 0.028 114.631 0.033
202109 -0.062 115.734 -0.072
202112 -0.032 117.630 -0.037
202203 -0.566 121.301 -0.630
202206 -0.198 125.017 -0.214
202209 -0.242 125.227 -0.261
202212 0.073 125.222 0.079
202303 -0.039 127.348 -0.041
202306 -0.053 128.729 -0.056
202309 -0.234 129.860 -0.243
202312 -0.187 129.419 -0.195
202403 -0.325 131.776 -0.333
202406 0.329 132.554 0.335
202409 0.205 133.029 0.208
202412 0.292 133.157 0.296
202503 -0.511 134.927 -0.511

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CareDx  (NAS:CDNA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


CareDx Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of CareDx's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CareDx Business Description

Traded in Other Exchanges
Address
8000 Marina Boulevard, Brisbane, CA, USA, 94005
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Executives
Christine Cournoyer director 150 SHAW ROAD, CHESTNUT MA 02467
Peter Maag director, officer: President and CEO CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Abhishek Jain officer: See Remarks C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Alexander L Johnson officer: Chief Business Officer C/O DIADEXUS, INC., 349 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Reginald Seeto officer: See Remarks C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Abraham Ronai officer: See Remarks C/O CAREDX, INC., 8000 MARINA BLVD, BRISBANE CA 94005
Grace Colon director C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Goldberg director 3000 SAND HILL ROAD, BUILDING 3, SUITE 290, MENLO PARK CA 94025
Ankur Dhingra officer: Chief Financial Officer C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Arthur A Torres director 87 BVENA VISTA TERRACE, SAN FRANCISCO CA 94117
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Sasha King officer: Chief Commercial Officer C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
William A Hagstrom director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Ralph Snyderman director C/O SAIC, 10260 CAMPUS POINT DR M/S F3, SAN DIEGO CA 92121